- The CytoSorbents ( NASDAQ: CTSO ) said the Turkish Ministry of Health approved national reimbursement for CytoSorb.
- CytoSorbents has a strategic collaboration with B?çakc?lar Medical Devices in Turkey.
- "Our partnership with B?çakc?lar was instrumental in obtaining national reimbursement and inclusion of CytoSorb in the healthcare catalog of the DMO. We look forward to working more closely with them to leverage our new reimbursement and expand the Turkish market for our products," said Christian Steiner, executive vice president, Sales and Marketing, CytoSorbents.
- CytoSorb is an extracorporeal blood purification method to reduce excess inflammatory mediators and elevated levels of bilirubin and myoglobin. The system is also used during and after cardiothoracic surgery to remove inflammatory mediators, according to the company.
For further details see:
CytoSorbents gets reimbursement for CytoSorb in Turkey